(Q36703814)

15 August 2017

Bupropion SR in adults with ADHD: a short-term, placebo-controlled trial (English)

1 reference

15 August 2017

0 references

Frederick W Reimherr

1

1 reference

15 August 2017

Dawson W Hedges

2

1 reference

15 August 2017

Robert E Strong

3

1 reference

15 August 2017

Barrie K Marchant

4

1 reference

15 August 2017

Erika D Williams

5

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 September 2005

1 reference

Neuropsychiatric Disease and Treatment

15 August 2017

1 reference

15 August 2017

1

1 reference

15 August 2017

3

1 reference

15 August 2017

245-251

1 reference

A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2416755

The stimulants revisited.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2416755

Attention-deficit/hyperactivity disorder in adults: an overview

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2416755

Controlled trial of high doses of pemoline for adults with attention-deficit/hyperactivity disorder

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2416755

Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2416755

Nortriptyline treatment of children with attention-deficit hyperactivity disorder and tic disorder or Tourette's syndrome

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2416755

Genetic and neurobiological aspects of attention deficit hyperactive disorder: a review.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2416755

Bupropion: a review of its mechanism of antidepressant activity.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2416755

Pharmacology of the enantiomers of threo-methylphenidate

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2416755

Neurobiology of attention deficit disorder with hyperactivity: where have we come in 50 years?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2416755

A double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2416755

Biological basis of depression and therapeutic relevance

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2416755

The assessment of social adjustment. A review of techniques

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2416755

Antidepressants reduce whole-body norepinephrine turnover while enhancing 6-hydroxymelatonin output

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2416755

Bupropion hydrochloride in attention deficit disorder with hyperactivity.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2416755

An open trial of venlafaxine in adult patients with attention deficit hyperactivity disorder

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2416755

Imipramine and methylphenidate treatments of hyperactive boys. A double-blind comparison

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2416755

A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2416755

Measurement of 3-methoxy-4-hydroxyphenylglycol (MHPG) in mouse brain by h.p.l.c. with electrochemical detection, as an index of noradrenaline utilisation and presynaptic alpha 2-adrenoceptor function

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2416755

Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2416755

Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2416755

Pharmacotherapy of attention-deficit/hyperactivity disorder in adults.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2416755

The use of imipramine in children's behavior disorders

5 September 2018

1 reference

12 December 2020

Current drug therapy recommendations for the treatment of attention deficit hyperactivity disorder

1 reference

12 December 2020

A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients

1 reference

12 December 2020

A naturalistic assessment of protriptyline for attention-deficit hyperactivity disorder

1 reference

12 December 2020

Treatment of childhood hyperactivity with desipramine: plasma drug concentration, cardiovascular effects, plasma and urinary catecholamine levels, and clinical response

1 reference

12 December 2020

Bupropion treatment of attention-deficit hyperactivity disorder in adults

1 reference

12 December 2020

Identifiers

1 reference

15 August 2017

PubMed publication ID

18568102

1 reference